Use of hyposensitization injections to control seasonal pruritus in a Bactrian camel (Camelus bactrianus).

J Zoo Wildl Med

Six Flags Marine World, 2001 Marine World Parkway, Vallejo, California 94589, USA.

Published: March 2005

A 9-yr-old, female Bactrian camel (Camelus bactrianus) developed severe pruritus in June 1993. During the next 8 yr, the camel exhibited annual episodes of pruritus and epiphora, generally beginning in June and subsiding in October of each year. These signs could usually be controlled with topical agents and fly repellents, although pruritus flare-ups were effectively controlled with intermittent injections of diphenhydramine and corticosteroids. There were no signs during the colder months. The pruritus became more severe and difficult to control when the camel reached its 18th year. Histopathologic descriptions of skin biopsies taken from several sites suggested a hypersensitivity reaction with secondary changes because of bacterial infection or corticosteroid administration (or both). An intradermal test (IDT) performed using 62 allergens regionalized to Northern California resulted in 17 positive test sites. Hyposensitization therapy was initiated using allergens chosen on the basis of exposure, availability, and the results of the IDT, using standard protocols. The clinical signs of pruritus were markedly reduced in the 2 yr after the hyposensitization injections were initiated.

Download full-text PDF

Source
http://dx.doi.org/10.1638/04-015DOI Listing

Publication Analysis

Top Keywords

hyposensitization injections
8
bactrian camel
8
camel camelus
8
camelus bactrianus
8
pruritus
6
injections control
4
control seasonal
4
seasonal pruritus
4
pruritus bactrian
4
camel
4

Similar Publications

Background: Hymenoptera venom allergy is a potentially severe allergic reaction in the general population. The only preventative approach in these cases is venom immunotherapy (VIT), which follows different protocols. The recommended initial dose is 0.

View Article and Find Full Text PDF

Allergen-specific immunotherapy is the only etiological treatment that can prevent the progression of allergic diseases at present. Cluster immunotherapy is an improved immunotherapy regimen, which shortens the dose escalation period from 4-6 months in conventional regimen to 1-8 weeks. In the past, there was no consensus or guideline to guide the standardized application of subcutaneous cluster immunotherapy of inhaled allergens in China.

View Article and Find Full Text PDF

Introduction: Sublingual immunotherapy (SLIT) is an effective and injection-free route for allergen-specific immunotherapy (AIT). Mesenchymal stromal/stem cell (MSC)-derived exosomes (Exo) has been identified as a novel delivery platform with immunomodulatory capacities. In addition, targeting agents such as aptamers (Apt) have been extensively used for specific delivery approaches such as direct delivery of allergen formulations to dendritic cells (DC) to improve the efficacy of specific immunotherapy.

View Article and Find Full Text PDF

Background: Allergies to fungi, such as , are significant contributors to respiratory conditions like asthma and rhinitis. Immunotherapy with native extracts often results in high rates of adverse reactions. This study evaluates the safety of immunotherapy using glutaraldehyde-polymerized extracts in both pediatric and adult populations.

View Article and Find Full Text PDF

Predictive value of Der p 2-specific IgE for subcutaneous immunotherapy in children with allergic rhinitis.

Sci Rep

October 2024

Department of Otorhinolaryngology, Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University, No. 819 Liyuan Roa, Haishu District, Ningbo, 315012, China.

Dermatophagoides pteronyssinus (Der p) subcutaneous immunotherapy (SCIT) has demonstrated efficacy in clinical trials of childhood allergic rhinitis (AR). Currently, there is a lack of some generally accepted biomarkers that may predict the clinical response to SCIT to eventually achieve personalized therapy. In this study, 28 children with AR received Der p SCIT for 26-30 months at baseline, and four efficacy endpoints, serum interleukin (IL)-5, periostin, Der p-specific IgE (sIgE), and Der p sIgG4, were measured by ELSIA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!